Please login to the form below

Not currently logged in


This page shows the latest HPV news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

Also on the agenda are preliminary clinical results with M7824, an investigational TGF‑beta trap/anti-PD-L1 bi-functional immunotherapy fusion protein in human papillomavirus (HPV)-associated cancers and

Latest news

More from news
Approximately 5 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Advancing women in healthcare Advancing women in healthcare

    She is especially proud of working to reduce the manufacturing costs of vaccines for diseases like human papillomavirus (HPV) and rotavirus, with the aim of these being more widely available in

  • Immunisation politicised Immunisation politicised

    Many countries objected to the HPV vaccine yet the vaccine was introduced rather rapidly in most countries. ... to do so, Austria became a 'European frontrunner' in gender-neutral HPV vaccination.

  • Deal Watch December 2015 Deal Watch December 2015

    200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of treatment for cancers induced by HPV.

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers.

  • Mapping KOL relationships Mapping KOL relationships

    In HPV, for example, influencers include virologists, immunologists, pathologists and epidemiologists.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...